August 3rd, 2010, Victory Pharma announced that it had completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals.

May 17th, 2010, MiddleBrook Pharmaceuticals had entered into an asset purchase agreement with Victory Pharma, Inc. for the sale of substantially all of its assets, and assumption of trade sales and certain other liabilities, of the Company for approximately $17.1 million (the "Acquisition"). The Acquisition is subject to customary closing conditions, a competitive auction process supervised by the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") in which MiddleBrook will seek competing bids to obtain the best offer possible for its assets, and approval of the Bankruptcy Court.

April 30th, 2010, MiddleBrook Pharmaceuticals had filed a voluntary petition (the "Petition") for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. MiddleBrook will continue to manage and operate its business and assets during the pendency of the bankruptcy case, subject to the supervision and orders of the Bankruptcy Court and in accordance with applicable provisions of the United States Bankruptcy Code.

In conjunction with the filing, MiddleBrook is seeking customary authority from the Bankruptcy Court that will enable it to continue operations and deliver products to customers in the ordinary course of business and without interruption.

The filing of the Petition places an automatic stay that restrains most actions a creditor could commence or continue against MiddleBrook and its assets, under applicable bankruptcy law, without the permission of the Bankruptcy Court. Stockholders of a company in Chapter 11 generally receive value only if all claims of the company's secured and unsecured creditors are fully satisfied. MiddleBrook is unsure if there will be value available for distribution to the common stockholders in the bankruptcy process, and therefore makes no guarantees that such claims will be satisfied.

June 28th, 2007, Advancis Pharmaceutical Corporation announced that it changed its name to MiddleBrook Pharmaceuticals, Inc.

MiddleBrook Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of pulsatile drug products for the treatment of infectious diseases.